Market Overview

UPDATE: Jefferies Raises PT on Merck & Co. on Positive Outlook

Share:
Related MRK
Merck Gets CHMP Positive Opinion For KEYTRUDA For Advanced Non-Small Cell Lung Cancer Treatment
Cramer Talks About Merck's 'Fabulous News' And Why The Market Can't Rally
Gilead Hepatitis C Pill Approved For Broad Use, Priced Below Sovaldi (Investor's Business Daily)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Hold rating on Merck & Co. (NYSE: MRK), and raised the price target from $46.00 to $48.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Merck & Co. closed on Tuesday at $45.51.

Latest Ratings for MRK

DateFirmActionFromTo
Jun 2016JefferiesMaintainsHold
May 2016Credit SuisseMaintainsNeutral
Apr 2016JefferiesMaintainsHold

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (MRK)

View Comments and Join the Discussion!